Tryptamine Director Buys More Shares

Tryptamine Therapeutics (AU:TYP) has released an update.

Jason Carroll, a director at Tryptamine Therapeutics Limited, has increased his stake in the company, purchasing 550,000 ordinary fully paid shares at $0.018 each, totaling $9,900. This on-market acquisition brings his total holding to 37,300,000 ordinary shares, with additional interests in options and other securities remaining unchanged.

For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.